The Influence of liraglutide dose on the effectiveness of microcirculatory disorders correction in white rats with absolute insulin deficiency
Year: 2021, volume 17 Issue: №2 Pages: 231-236
Heading: Рathophysiology Article type: Original article
Authors: Lagutina D.D., Stepanova T.V., Savkina A.A., Ivanov A.N.
Organization: Saratov State Medical University
Heading: Рathophysiology Article type: Original article
Authors: Lagutina D.D., Stepanova T.V., Savkina A.A., Ivanov A.N.
Organization: Saratov State Medical University
Summary:
The aim is to study of the dose-dependent effects of glucagon-like peptide-1 receptors agonist liraglutide on the microcirculation of white rats under the alloxan-induced insulin deficiency. Material and methods. The studies were carried out on 70 white rats, divided into 4 groups: 20 control intact animals, 20 animals of the comparison group with alloxan diabetes, 10 animals with insulin deficiency, which were injected with liraglutide at a dose of 0.2 mg/kg/day (experimental group No 1) and, 20 animals with insulin deficiency of which were treated with liraglutide at a dose of 0.4 mg/kg/day (experimental group No 2). Diabetic status, skin perfusion of the posterior paw and mechanisms of blood flow modulation were assessed in all groups of animals. Results. It was found that the administration of liraglutide at a dosage of 0.4 mg/kg/day allows achieving complete normalization of carbohydrate metabolism in rats with alloxan-induced insulin deficiency, and it is more effectively improves the state of microcirculation compared with the use of a dosage of 0.2 mg/kg/day. Conclusion. The effectiveness of the correction of microcirculatory disorders with liraglutide correlates to the correction of carbohydrate metabolism in rats with insulin deficiency and depends on the dose of the drug. The dose-dependent effect is determined by the endothelial mechanism of microcirculation modulation. At the same time, the restoration of the neurogenic component of the vasculartone is independent from the dose of liraglutide.
Bibliography:
1. Dedov II, Shestakova MV, Vikulova OK. Epidemiology of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal Register of Diabetes Mellitus. Diabetes mellitus 2017; 20 (1): 13-41.
2. Strain WD, Paldanius РМ. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol 2018; 17 (1):57.
3. Dal Canto E, Ceriello A, Ryden L, et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 2019; 26 (2): 25-32.
4. Bjerg L, Hulman A, Carstensen B, et al. Effect of duration and burden of microvascular complications on mortality rate in type 1 diabetes: an observational clinical cohort study. Diabetologia 2019; 62 (4): 633-43.
5. Knapp M, Tu X, Wu R. Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy. Acta Pharmacol Sin 2019; 40(1): 1-8.
6. Arcaro G, Cretti A, Balzano S, et al. Insulin causes endothelial dysfunction in humans, sites and mechanisms. Circulation 2002; (105): 576-82.
7. Zhang X, Shao F, Zhu L, et al. Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A meta-analysis of randomized
controlled cardiovascular outcome trials with trial sequential analysis. ВМС Pharmacol Toxicol 2018; 19 (1): 58.
8. Dimitrios P, Michael D, Vasilios K. Liraglutide as adjunct to insulin treatment in patients with type 1 diabetes: A systematic review and meta-analysis. Curr Diabetes Rev 2020; 16 (4): 313-26.
9. Simanenkova AV, Makarova MN, Vasina LV, et al. Glucagon-like peptide-1 receptor agonist diminishes endothelial dysfunction in type 2 diabetic patients. Regional blood circulation and microcirculation 2018; 17 (2): 57-63.
10. Buxtiyarova IP, DrogovozSM, Shhekina EG. Investigation of the hypoglycemic properties of raleukin on a model of alloxan diabetes in rats. Vestnik Kaz NMU 2014; (4): 301-4.
11. Zhang Q, Xiao X, Zheng J, et al. Liraglutide protects cardiac function in diabetic rats through the PPARa. Biosci Rep 2018; 38 (2): BSR20180059.
12. Ivanov AN, Antipova ON, Savkina AA, et al. Effect of liraglutide on microcirculation in rats with experimental diabetes mellitus associated with absolute insulin deficiency. Regional hemodynamics and microcirculation 2020; 19 (4): 61-9.
13. Sukumaran V, Tsuchimochi Н, Sonobe Т, et al. Liraglutide treatment improves the coronary microcirculation in insulin
resistant Zucker obese rats on a high salt diet. Cardiovasc Diabetol 2020; (19): 24.
14. Popyhova EB, Stepanova TV, Lagutina DD, et al. The role of diabetes in the onset and development of endothelial dysfunction. Problems of Endocrinology 2020; 66 (1): 47-55.
15. Dos Santos JM, Tewari S, Mendes RH. The role of oxidative stress in the development of diabetes mellitus and its complications. J Diabetes Res 2019; (5): 4189813.
16. Faber R, Zander M, Pena A, et al. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes — a randomized, single-blinded, cross-over pilot study. Cardiovasc Diabetol 2015; (14): 41.
17. Ishibashi Y, Matsui T, Takeuchi M, et al. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE) — induced upregulation of VCAM-1. Biochem Biophys Res Commun 2010; (391): 1405-8.
18. Chai W, Dong Z, Wang N, et al. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 2012; (62): 888-96.
19. Krupatkin Al, Sidorov VV. Laser Doppler flowmetry of blood microcirculation: A guide for doctors. Moscow: Medicina, 2005; 256 p.
20. Ivanov AN, Grechikhin AA, Norkin IA, et al. Methods of endothelial dysfunction diagnosis. Regional blood circulation and microcirculation 2014; 13 (4): 4-11.
| Attachment | Size |
|---|---|
| 2021_02_231-236.pdf | 528.28 KB |
Русский
English